(Q40915177)

24 September 2017

1 reference

title

Assessment of pain in herpes zoster: lessons learned from antiviral trials (English)

1 reference

24 September 2017

1 reference

1 reference

Anthony L. Cunningham

3

1 reference

24 September 2017

Dworkin RH

1

1 reference

24 September 2017

Carrington D

2

1 reference

24 September 2017

Kost RG

4

1 reference

24 September 2017

Levin MJ

5

1 reference

24 September 2017

McKendrick MW

6

1 reference

24 September 2017

Oxman MN

7

1 reference

24 September 2017

Rentier B

8

1 reference

24 September 2017

Schmader KE

9

1 reference

24 September 2017

Tappeiner G

10

1 reference

24 September 2017

Wassilew SW

11

1 reference

24 September 2017

Whitley RJ

12

1 reference

24 September 2017

publication date

1 January 1997

1 reference

24 September 2017

1 reference

24 September 2017

volume

33

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

73-85

1 reference

Hypotheses on the pathogenesis of herpes zoster-associated pain

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

The natural history of herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

The outcome of patients with herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Pain and its persistence in herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Herpes zoster and quality of life: a self-limited disease with severe impact.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

The McGill Pain Questionnaire: Major properties and scoring methods

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

The short-form McGill Pain Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Geriatric herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Post-herpetic neuralgia: Further post-mortem studies of cases with and without pain

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

How should zoster trials be conducted?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901007-8

7 January 2021

10.1016/S0166-3542(96)01007-8

Identifiers

DOI

1 reference

24 September 2017

1 reference